Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00768300
Registration number
NCT00768300
Ethics application status
Date submitted
7/10/2008
Date registered
8/10/2008
Date last updated
8/04/2014
Titles & IDs
Public title
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
Query!
Scientific title
ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)
Query!
Secondary ID [1]
0
0
GS-US-231-0101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ARTEMIS-IPF
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ambrisentan
Treatment: Drugs - Placebo
Experimental: Ambrisentan -
Placebo Comparator: Placebo -
Treatment: Drugs: Ambrisentan
Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
Treatment: Drugs: Placebo
Placebo to match ambrisentan was administered orally once daily.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to Death or Disease (IPF) Progression.
Query!
Assessment method [1]
0
0
The median time to death or disease progression was based on Kaplan-Meier (KM) estimates of pooling over strata, and was defined as the first occurrence of any of the following:
Either 1) a decrease of = 10% in FVC (L) and a decrease of = 5% in diffuse lung capacity for carbon monoxide (DLCO) (ml/min/mmHg), or 2) a decrease of = 5% in FVC (L) and a decrease of = 15% in DLCO (ml/min/mmHg); deterioration in FVC and DLCO must be confirmed at the subsequent visit within 28 (± 14) days
Respiratory hospitalization (hospitalization involving worsening of, or deterioration in respiratory symptoms, gas exchange/hypoxemia, or radiographic findings on chest x-ray or high-resolution computerised tomography (HRCT) scan
All-cause mortality
Query!
Timepoint [1]
0
0
Up to 48 months
Query!
Secondary outcome [1]
0
0
Proportion of Participants With No Disease Progression or Death at 48 Weeks
Query!
Assessment method [1]
0
0
The proportion of participants with no disease progression or death is presented as a percentage using a Kaplan-Meier (KM) estimate of survival or not experiencing disease progression.
Query!
Timepoint [1]
0
0
Baseline and Week 48
Query!
Secondary outcome [2]
0
0
Change in FVC % Predicted at Week 48
Query!
Assessment method [2]
0
0
FVC is defined as the volume of air (liters) that can forcibly be blown out after taking a full breath. FVC % predicted is defined as FVC % of the participant divided by the average FVC % in the population for any person of similar age, sex, and body composition.
Query!
Timepoint [2]
0
0
Baseline and Week 48
Query!
Secondary outcome [3]
0
0
Change in DLCO % Predicted at Week 48
Query!
Assessment method [3]
0
0
DLCO is the extent to which oxygen passes from the air sacs of the lungs into the blood. DLCO % predicted is defined as DLCO % of the participant divided by the average DLCO % in the population for any person of similar age, sex and body composition.
Query!
Timepoint [3]
0
0
Baseline and Week 48
Query!
Secondary outcome [4]
0
0
Change in 6MWT at Week 48
Query!
Assessment method [4]
0
0
The 6MWT is a measure of exercise tolerance, and measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface.
Query!
Timepoint [4]
0
0
Baseline and Week 48
Query!
Secondary outcome [5]
0
0
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the Short-Form 36® (SF-36)
Query!
Assessment method [5]
0
0
The range of each health domain score is 0-100, with 0 indicating a poorer health state and 100 indicating a better health state. An increase in score indicates an improvement in health state.
Query!
Timepoint [5]
0
0
Baseline and Week 48
Query!
Secondary outcome [6]
0
0
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the St. George's Respiratory Questionnaire (SGRQ)
Query!
Assessment method [6]
0
0
The SGRQ is designed to measure impact on overall health, daily life, and perceived well-being in participants with obstructive airways disease. The range of each score is 0-100, with 0 indicating fewer limitations and 100 indicating more limitations; an increase in score indicates an increase in limitations.
Query!
Timepoint [6]
0
0
Baseline and Week 48
Query!
Secondary outcome [7]
0
0
Change in Dyspnea Score at Week 48 as Assessed by the Transitional Dyspnea Index (TDI)
Query!
Assessment method [7]
0
0
The transitional focal score (-9 to 9) is the sum of relative change from baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores (each -3 to 3 scale). A TDI score of -9 represents a maximum degradation of all three tests; a score of 9 represents a maximum improvement of all three tests.
Query!
Timepoint [7]
0
0
Baseline and Week 48
Query!
Secondary outcome [8]
0
0
Percentage of Participants Who Developed PH on Study
Query!
Assessment method [8]
0
0
The percentage of participants known to have developed pulmonary hypertension on study documented by right heart catheterization (RHC) was analyzed. RHC was done at baseline and 48 weeks, or at the early termination visit.
Query!
Timepoint [8]
0
0
Up to 48 weeks
Query!
Eligibility
Key inclusion criteria
- Male or females from 40 to 80 years of age
- Diagnosis of IPF
- Honeycombing (fibrosis in the lung) on high-resolution computerised tomography (HRCT)
scan of less than or equal to 5%
- Willing and able to have 2 right heart catheterizations performed
- Willing to have monthly lab tests to monitor liver function
- Able to perform the 6 minute walk test (indicated adequate physical function)
- Must have meet lung function requirements
- Normal liver function tests
- Negative serum pregnancy test
- Willing to use at least 2 reliable methods of contraception
- Able to understand and willing to sign informed consent form
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- No restrictive lung disease (other than usual interstitial pneumonia or IPF)
- No obstructive lung disease
- No recent or active respiratory exacerbations
- No recent hospitalization for an IPF exacerbation
- No recent history of alcohol abuse
- Chronic sildenafil (or same drug class) use for pulmonary hypertension
- Chronic treatment with certain medications for IPF within 30 days of randomization
- No other serious medical conditions
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
494
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
- Concord
Query!
Recruitment hospital [2]
0
0
- Darlinghurst
Query!
Recruitment hospital [3]
0
0
- Chermside
Query!
Recruitment hospital [4]
0
0
- Woodville
Query!
Recruitment hospital [5]
0
0
- Hobart
Query!
Recruitment hospital [6]
0
0
- Parkville
Query!
Recruitment hospital [7]
0
0
- Prahran
Query!
Recruitment hospital [8]
0
0
- Perth
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [4]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [5]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [6]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [7]
0
0
3181 - Prahran
Query!
Recruitment postcode(s) [8]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Delaware
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Minnesota
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Hampshire
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Jersey
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Tennessee
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Utah
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Virginia
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Washington
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Provincia de Buenos Aires
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Buenos Aires
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Mar del Plata, Buenos Aires
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
San Miguel de Tucuman
Query!
Country [34]
0
0
Austria
Query!
State/province [34]
0
0
Graz
Query!
Country [35]
0
0
Austria
Query!
State/province [35]
0
0
Innsbruck
Query!
Country [36]
0
0
Austria
Query!
State/province [36]
0
0
Linz
Query!
Country [37]
0
0
Austria
Query!
State/province [37]
0
0
Wien
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Anderlecht
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Bruxelles
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Leuven
Query!
Country [41]
0
0
Belgium
Query!
State/province [41]
0
0
Yvoir
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Belo Horizonte
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Florianopolis
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
Goiania
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Porto Alegre
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Rio de Janeiro
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
Santo Andre
Query!
Country [48]
0
0
Brazil
Query!
State/province [48]
0
0
Sao Paolo
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Alberta
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
British Columbia
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Newfoundland and Labrador
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Quebec
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Toronto
Query!
Country [54]
0
0
Chile
Query!
State/province [54]
0
0
Santiago
Query!
Country [55]
0
0
Chile
Query!
State/province [55]
0
0
Talcahuano
Query!
Country [56]
0
0
Chile
Query!
State/province [56]
0
0
Valparaiso
Query!
Country [57]
0
0
Colombia
Query!
State/province [57]
0
0
Bogota
Query!
Country [58]
0
0
Colombia
Query!
State/province [58]
0
0
Floridablanca
Query!
Country [59]
0
0
Czech Republic
Query!
State/province [59]
0
0
Brno
Query!
Country [60]
0
0
Czech Republic
Query!
State/province [60]
0
0
Hradec Kralove
Query!
Country [61]
0
0
Czech Republic
Query!
State/province [61]
0
0
Jihlava
Query!
Country [62]
0
0
Czech Republic
Query!
State/province [62]
0
0
Liberec
Query!
Country [63]
0
0
Czech Republic
Query!
State/province [63]
0
0
Olomouc
Query!
Country [64]
0
0
Czech Republic
Query!
State/province [64]
0
0
Plzen
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Lille
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Marseille
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Montpellier
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Nice
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Paris
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Pessac
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Rennes
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Tours
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Berlin
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Coswig
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Donaustauf
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Essen
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Freiburg
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Greifswald
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Heidelberg
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Lowenstein
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Munchen
Query!
Country [82]
0
0
Ireland
Query!
State/province [82]
0
0
Dublin
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Ashkelon
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Beer-Sheva
Query!
Country [85]
0
0
Israel
Query!
State/province [85]
0
0
Haifa
Query!
Country [86]
0
0
Israel
Query!
State/province [86]
0
0
Jerusalem
Query!
Country [87]
0
0
Israel
Query!
State/province [87]
0
0
Petach Tikva
Query!
Country [88]
0
0
Israel
Query!
State/province [88]
0
0
Rehovot
Query!
Country [89]
0
0
Israel
Query!
State/province [89]
0
0
Tel Aviv
Query!
Country [90]
0
0
Israel
Query!
State/province [90]
0
0
Tel-Hashomer
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Catania
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Forlì
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Milano
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Modena
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Napoli
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Padova
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Palermo
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Roma
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Siena
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Torino
Query!
Country [101]
0
0
Mexico
Query!
State/province [101]
0
0
Jalisco
Query!
Country [102]
0
0
Mexico
Query!
State/province [102]
0
0
Nuevo Leon
Query!
Country [103]
0
0
Mexico
Query!
State/province [103]
0
0
Huixquilucan Edo. de Mexico
Query!
Country [104]
0
0
Mexico
Query!
State/province [104]
0
0
Mexico City, DF
Query!
Country [105]
0
0
Mexico
Query!
State/province [105]
0
0
Monterrey
Query!
Country [106]
0
0
Mexico
Query!
State/province [106]
0
0
Zapopan, Jalisco
Query!
Country [107]
0
0
Netherlands
Query!
State/province [107]
0
0
Almelo
Query!
Country [108]
0
0
Peru
Query!
State/province [108]
0
0
Callao
Query!
Country [109]
0
0
Peru
Query!
State/province [109]
0
0
Lima
Query!
Country [110]
0
0
Poland
Query!
State/province [110]
0
0
Bydgoszcz
Query!
Country [111]
0
0
Poland
Query!
State/province [111]
0
0
Lodz
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Andalucia
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Asturias
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Castilla
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Galicia
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Madrid, Communidad de
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Badalona
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Barcelona
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Madrid
Query!
Country [120]
0
0
Switzerland
Query!
State/province [120]
0
0
Basel
Query!
Country [121]
0
0
Switzerland
Query!
State/province [121]
0
0
Bern
Query!
Country [122]
0
0
Switzerland
Query!
State/province [122]
0
0
Lausanne
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
South Yorkshire
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Surrey
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Cambridge
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
Chelmsford
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
Edinburgh
Query!
Country [128]
0
0
United Kingdom
Query!
State/province [128]
0
0
Glasgow
Query!
Country [129]
0
0
United Kingdom
Query!
State/province [129]
0
0
Liverpool
Query!
Country [130]
0
0
United Kingdom
Query!
State/province [130]
0
0
London
Query!
Country [131]
0
0
United Kingdom
Query!
State/province [131]
0
0
Mancesheter
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Gilead Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying
disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to
evaluate its safety, and to evaluate its effect on development of pulmonary hypertension,
quality of life, and dyspnea (shortness of breath) symptoms in this participant population.
Participants were randomized in a 2:1 ratio to receive ambrisentan or placebo, respectively.
Participation in the study was to be up to 4 years, depending on how long it would take to
enroll participants and observe study events. After randomization, visits to the clinic took
place every 3 months, and laboratory procedures were performed every month.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00768300
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Ganesh Raghu, MD
Query!
Address
0
0
University of Washington, Div. of Pulmonary and Critical Care Medicine Chair
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00768300
Download to PDF